The ionotropic glutamate receptor subunit, GluK1 (GluR5), is expressed in many regions of the nervous system related to sensory transmission. Recently, a selective ligand for the GluK1 receptor, , was synthesized as a derivative of dysiherbaine, a toxin isolated from the marine sponge Lendenfeldia chondrodes. MSVIII-19 potently desensitizes GluK1 receptors without channel activation, rendering it useful as a functional antagonist. Given the high selectivity for GluK1 and the proposed role for this glutamate receptor in nociception, we sought to test the analgesic potential of MSVIII-19 in a series of models of inflammatory, neuropathic, and visceral pain in mice. MSVIII-19 delivered intrathecally dose-dependently reduced formalin-induced spontaneous behaviors and reduced thermal hypersensitivity 3 hours after formalin injection and 24 hours after complete Freund's adjuvantinduced inflammation, but had no effect on mechanical sensitivity in the same models. Intrathecal MSVIII-19 significantly reduced both thermal hyperalgesia and mechanical hypersensitivity in the chronic constriction injury model of neuropathic pain, but had no effect in the acetic acid model of visceral pain. Peripheral administration of MSVIII-19 had no analgesic efficacy in any of these models. Finally, intrathecal MSVIII-19 did not alter responses in Tail-flick tests or performance on the accelerating RotaRod. These data suggest that spinal administration of MSVIII-19 reverses hypersensitivity in several models of pain in mice, supporting the clinical potential of GluK1 antagonists for the management of pain.
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Introduction
Glutamate is the primary excitatory neurotransmitter in the mammalian central nervous system and exerts its effects via activation of a large number of receptors that include both G-protein coupled metabotropic receptors and ligand-gated ion channels known as ionotropic glutamate receptors [9] . Kainate receptors represent a subset of ionotropic glutamate receptors (iGluRs) that are potently activated by the natural products kainic acid and domoic acid. The other members of the iGluR family, AMPA and NMDA receptors, play prominent roles in mediating excitatory synaptic transmission and plasticity in the brain, whereas the roles of kainate receptors in the nervous system are less well understood [3] .
Kainate receptors are heteromeric channels formed by combinations of five different gene products, GluK1-5, which were formerly known as GluR5, GluR6, GluR7, KA1, and KA2 [3] . Several recent studies provided evidence that receptors primarily comprised of the GluK1 subunit are important in transmission in nociceptive pathways, particularly in the context of persistent pain states [13, 16] . GluK1 is expressed at many levels of the pain neuraxis, including the dorsal root ganglion, the spinal cord dorsal horn, and in central neurons in many areas involved in pain transmission or perception. Previous studies of the role of GluK1 in rodent models of pain have used gene knockout mice [16] or drugs administered via systemic or intracisternal routes, making localization of the functionally important sites difficult [5, 13, 25] . Spinally administered GluK1 receptor antagonists have been shown to reduce responses of spinothalamic tract neurons to noxious stimuli in primates [21] , suggesting that GluK1 receptors expressed in the cord might be important in mediating analgesic actions of systemically applied antagonists and reduced pain in GluK1-deficient mice. 
